Loading…

Phase II clinical trial of a vas deferens injectable contraceptive for the male

Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific do...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 1997-10, Vol.56 (4), p.245-250
Main Authors: Guha, Sujoy K., Singh, Gulshanjit, Ansari, Shirfuddin, Kumar, Sudheer, Srivastava, Anil, Koul, Veena, Das, H.C., Malhotra, R.L., Das, S.K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented. Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results reconfirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.
ISSN:0010-7824
1879-0518
DOI:10.1016/S0010-7824(97)00142-X